Malaria vaccine deployment in Africa advances rapidly but faces sustainability threats from funding reductions and climate pressures
Introduction
Two reports detail the current state of malaria vaccine implementation in Africa. One describes a field trial in Tanzania for the R21 vaccine, which has led to a substantial reduction in local cases, while the other outlines the continent-wide rollout coordinated by Gavi, the Vaccine Alliance, now active in 25 countries. Both accounts highlight significant progress but also underscore vulnerabilities arising from foreign aid cuts and the evolving epidemiological landscape shaped by climate change.
Main Body
Malaria remains a leading cause of mortality in sub-Saharan Africa, with children under five accounting for over three-quarters of global deaths. In Tanzania, the disease is endemic: in 2024, the country recorded 9.4 million cases and 26,000 deaths. The global burden has worsened, with worldwide deaths rising from 598,000 in 2023 to 610,000 in 2024, driven partly by antimicrobial resistance and climate change. In the village of Mwavi, Bagamoyo District, participation in a trial for the R21 vaccine—developed by Oxford University’s Jenner Institute and approved by the WHO in 2023—has been associated with a reported 90% decline in malaria infections over five years. Dr Angela Gwakisa, the overseeing clinician, confirmed that data show a reduction in cases, which has been amplified by booster doses. The vaccine also indirectly protects adults by interrupting parasite transmission from humans to mosquitoes. Residents expressed appreciation for the intervention, with one mother gifting 21 pineapples to the clinician. At the continental level, Gavi reports that the malaria vaccine rollout is the fastest in its history. Twenty-five African countries have integrated the vaccine into routine immunisation programmes. Early data from Kenya, Malawi, Ghana, and Cameroon indicate reductions in severe disease and hospital admissions among vaccinated children. In Burkina Faso, a combination of vaccination, bed nets, seasonal chemoprevention, and community mobilisation contributed to a 32% decline in reported malaria cases between 2024 and 2025, with child deaths nearly halved. Gavi’s Chief Country Delivery Officer, Thabani Maphosa, noted that the speed of rollout reflects high country demand and extensive pre-planning. However, delivering the recommended four doses per child poses logistical challenges, particularly for the fourth dose administered later. Countries have adopted phased, context-specific strategies, and Gavi has invested $5 million in a learning agenda across seven nations to identify effective delivery methods. Despite these advances, the sustainability of malaria control programmes is threatened by reductions in foreign aid. The closure of the US Agency for International Development (USAID) resulted in a loss of $216 million in aid to Tanzania alone, affecting approximately 5,000 healthcare workers involved in HIV and malaria prevention. Residents of Mwavi reported that USAID-branded vehicles no longer distribute mosquito nets, and some malaria medications are intermittently unavailable. The R21 trial in Bagamoyo is nearing completion, and while approval for routine use appears likely given prior adoptions in Nigeria and Ghana, the Tanzanian government’s capacity to fund inclusion in the national immunisation schedule remains uncertain. Dr Maxmillian Mpina, overseeing a trial for the RTSS vaccine, stated that the health system will continue to feel the impact of aid cuts as the government reorganises its budget to compensate for the sudden funding loss. Research institutions are also affected. The Ifakara Health Institute, which oversees both vaccine trials, lost a $15 million annual USAID programme that employed 800 people. Dr Brian Tarimo, working on genetically engineered mosquitoes, noted that redeployment of foundation money has delayed other research streams. Dr Sarah Moore, evaluating vector control products, described research funding as “decimated,” with reduced capacity to take on PhD students and attend WHO consultations. The WHO estimates that the $3.9 billion annually invested in malaria eradication is less than half the $9.3 billion required, and current aid cuts are likely to lower that figure further. Dr Moore emphasised that even a major technological breakthrough would require substantial investment in production and implementation, citing polio eradication as an example where a lifelong vaccine has not yet achieved full coverage due to logistical challenges. Medicines for Malaria Venture (MMV), which has developed 19 antimalarial drugs since 1999 through public-private partnerships, treats an estimated 1.5 billion people. CEO Martin Fitchet stressed that grant-based financing is essential for both drug development and health system delivery, warning that stopping funding for health systems leads to immediate deaths, while halting R&D causes future fatalities. Gavi’s Maphosa echoed this, stating that fully funding the malaria programme is critical to prevent increased child mortality, household impoverishment from healthcare costs, and strain on health systems. He called for sustained investment in integrated programmes combining vaccines, chemoprevention, vector control, diagnostics, and treatment, and noted that continued R&D is needed for second-generation vaccines with higher efficacy and simpler dosing. The current vaccines, RTS,S and R21, are described as first-generation tools that save lives today while building the evidence and market conditions for future innovations.
Conclusion
The rapid expansion of malaria vaccination across Africa represents a significant public health achievement, with early evidence showing reduced severe disease and mortality. However, this progress is contingent on sustained financial commitment from both domestic governments and international donors. Funding cuts, particularly from USAID, have already disrupted distribution networks and research programmes in Tanzania. Without adequate and consistent investment, the gains made through vaccination and complementary interventions risk being reversed, leaving vulnerable populations—especially young children—exposed to a disease that remains a leading cause of death on the continent.